ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
High-Risk Bleeding in Acute Myeloid Leukemia: Clinical Presentation, Laboratory Markers, and Mortality Trends.
Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Von Willebrand, factor VIII, and D-dimer levels as predictors of risk and clinical outcomes in acute myeloid leukemia.Clinical and experimental medicine · 2026Article
- Postoperative complications in patients with chemotherapy-induced acute myeloid leukemia (Review).Oncology letters · 2026Review
- Subacute Coronary Stent Thrombosis as the Initial Presentation of Acute Myeloid Leukemia: A Case Report and Literature Review.Journal of investigative medicine high impact case reportsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundSevere bleeding is a major complication in acute myeloid leukemia (AML), contributing to early mortality. While thrombocytopenia and coagulopathy are known risk factors, the clinical and laboratory features surrounding haemorrhagic events in real-world AML cohorts require further elucidation.ObjectivesTo assess the frequency, sites, clinical features, laboratory findings, and outcomes of Grade ≥3 bleeding in AML patients.MethodsThis retrospective study reviewed 214 AML patients treated between 2012 and 2021 at a tertiary centre in Qatar. Patients with WHO Grade ≥3 bleeding were analysed for clinical, laboratory, cytogenetic, and outcome data.ResultsThirty-five patients (16.3%) had Grade ≥3 bleeding, most commonly intracranial (86%), presenting with neurological symptoms (80%). Events occurred mainly during or soon after induction chemotherapy (40%). Median haemoglobin and platelet count at bleeding were 7.1 g/dL and 11 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.